2024
Liquid biopsy‐based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results
Mata D, Lee J, Shanmugam V, Marcus C, Schrock A, Williams E, Ritterhouse L, Hickman R, Janovitz T, Patel N, Kroger B, Ross J, Mirza K, Oxnard G, Vergilio J, Elvin J, Benhamida J, Decker B, Xu M. Liquid biopsy‐based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results. Histopathology 2024, 84: 1224-1237. PMID: 38422618, DOI: 10.1111/his.15168.Peer-Reviewed Original ResearchConceptsNon-Hodgkin's lymphomaPlasma-cell neoplasmsAcute myeloid leukemiaCirculating tumor DNAHodgkin lymphomaMyelodysplastic syndromeHaematopoietic neoplasmsNext-generation sequencingTissue-based NGSMaximum somatic allele frequencyFoundationOne Liquid CDxTherapy-resistant clonesRelevant genomic alterationsPositive percent agreementPotential clinical utilityLymphoid malignanciesTumor DNAMyeloid leukemiaPlasma-cellsTissue biopsiesGenomic alterationsPathogenic alterationsLiquid biopsyMolecular profilingTP53
2022
Liquid Biopsy-Based Next-Generation Sequencing Is an Alternative to Tissue Molecular Profiling of Lymphoid, Plasma-Cell, and Myeloid Neoplasms
Mata D, Lee J, Decker B, Shanmugam V, Marcus C, Tukachinsky H, Schrock A, Patel N, Ross J, Oxnard G, Vergilio J, Mirza K, Xu M, Benhamida J. Liquid Biopsy-Based Next-Generation Sequencing Is an Alternative to Tissue Molecular Profiling of Lymphoid, Plasma-Cell, and Myeloid Neoplasms. Blood 2022, 140: 1205-1207. DOI: 10.1182/blood-2022-159106.Peer-Reviewed Original ResearchSpatial profiling of chromatin accessibility in mouse and human tissues
Deng Y, Bartosovic M, Ma S, Zhang D, Kukanja P, Xiao Y, Su G, Liu Y, Qin X, Rosoklija GB, Dwork AJ, Mann JJ, Xu ML, Halene S, Craft JE, Leong KW, Boldrini M, Castelo-Branco G, Fan R. Spatial profiling of chromatin accessibility in mouse and human tissues. Nature 2022, 609: 375-383. PMID: 35978191, PMCID: PMC9452302, DOI: 10.1038/s41586-022-05094-1.Peer-Reviewed Original ResearchConceptsChromatin accessibilityATAC-seqSpecific epigenetic landscapesChromatin accessibility profilingCell fate decisionsEpigenetic informationEpigenetic landscapeGenome scaleFate decisionsAccessible genomeCell identityEpigenetic underpinningsNext-generation sequencingGene regulatorsCell statesMouse embryosSpatial biologySpatial transcriptomicsCell typesCellular levelImmune cell typesDistinct organizationHuman tissuesProfilingSpatial profiling
2019
EBV-Positive Primary Large B-Cell Lymphoma: The Role of Immunohistochemistry and XPO1 in the Diagnosis of Mediastinal Lymphomas
Maracaja DLV, Puthenpura V, Pels SG, O’Malley D, Sklar JL, Finberg KE, Xu ML. EBV-Positive Primary Large B-Cell Lymphoma: The Role of Immunohistochemistry and XPO1 in the Diagnosis of Mediastinal Lymphomas. Applied Immunohistochemistry & Molecular Morphology 2019, 28: 725-730. PMID: 31789821, DOI: 10.1097/pai.0000000000000820.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkers, TumorDiagnosis, DifferentialEpstein-Barr Virus InfectionsHerpesvirus 4, HumanHigh-Throughput Nucleotide SequencingHumansImmunohistochemistryImmunophenotypingKaryopherinsLymphoma, Large B-Cell, DiffuseMaleMediastinal NeoplasmsMutationReceptors, Cytoplasmic and NuclearThymus NeoplasmsYoung AdultConceptsPrimary mediastinal large B-cell lymphomaEpstein-Barr virusLarge B-cell lymphomaB-cell lymphomaEBV positivityMediastinal lymphomaMediastinal large B-cell lymphomaMediastinal gray zone lymphomaGray zone lymphomaRole of immunohistochemistryClassical Hodgkin lymphomaEBV expressionMediastinal massTherapeutic optionsHodgkin's lymphomaClassic immunophenotypeLymphomaXPO1 mutationsMutational profilingPositivityNext-generation sequencingImmunophenotypeSomatic mutationsK mutationTumors